

Hepatitis B & C Therapeutics Market - 2024-2033

<https://marketpublishers.com/r/H6012651D208EN.html>

Date: February 2026

Pages: 213

Price: US\$ 2,999.00 (Single User License)

ID: H6012651D208EN

Abstracts

The Hepatitis B & C Therapeutics Market was valued at US\$ 17.02 billion in 2024 and is anticipated to reach US\$ 20.83 billion by 2033, at a CAGR of 0.034 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Hepatitis B & C Therapeutics Market.

This report delivers a comprehensive overview of the Hepatitis B & C Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Hepatitis B & C Therapeutics Market. The Hepatitis B & C Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

Hepatitis B & C Therapeutics Market Scope:

Key Players

Gilead Sciences, Inc

AbbVie Inc.

Bristol-Myers Squibb Company

Merck & Co., Inc.

Johnson & Johnson

Roche Holding AG

Dynavax Technologies Corporation

VBI Vaccines

Major Highlights

This report delivers a comprehensive overview of the Hepatitis B & C Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Hepatitis B & C Therapeutics Market. The Hepatitis B & C Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients

with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. MARKET INTRODUCTION AND SCOPE

- 1.1. Objectives of the Report
- 1.2. Report Coverage & Definitions
- 1.3. Report Scope

2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS

3. MARKET HIGHLIGHTS AND STRATEGIC TAKEAWAYS

- 3.1. Key Trends and Future Projections
- 3.2. Snippet by Therapeutic Class
- 3.3. Snippet by Indication
- 3.4. Snippet by Route of Administration
- 3.5. Snippet by Distribution Channel
- 3.6. Snippet by Region

4. DYNAMICS

- 4.1. Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. Rising Global Disease Burden
 - 4.1.1.2. Advancements in Therapeutics & Vaccines
 - 4.1.2. Restraints
 - 4.1.2.1. High Treatment Costs and Limited Access
 - 4.1.2.2. Lack of Awareness and Screening Programs
 - 4.1.3. Opportunity
 - 4.1.3.1. Emerging Curative & Combination Therapies

5. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK

- 5.1. Market Leaders and Pioneers
 - 5.1.1. Emerging Pioneers and Prominent Players
 - 5.1.2. Established Leaders with the Largest Marketing Brand
 - 5.1.3. Market Leaders with Established Products
- 5.2. Latest Developments and Breakthroughs
- 5.3. Regulatory and Reimbursement Landscape

- 5.3.1. North America
- 5.3.2. Europe
- 5.3.3. Asia Pacific
- 5.3.4. South America
- 5.3.5. Middle East & Africa
- 5.4. Porter's Five Forces Analysis
 - 5.4.1. Bargaining power of suppliers
 - 5.4.2. Bargaining power of buyers
 - 5.4.3. Threat of substitutes
 - 5.4.4. Threat of new entrants
 - 5.4.5. Competitive rivalry
- 5.5. Unmet Needs and Gaps
- 5.6. Recommended Strategies for Market Entry and Expansion
- 5.7. Pricing Analysis and Price Dynamics

6. GLOBAL HEPATITIS B AND C THERAPEUTICS MARKET, BY THERAPEUTIC CLASS

- 6.1. Introduction
 - 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Class
 - 6.1.2. Market Attractiveness Index, By Therapeutic Class
- 6.2. Nucleoside/Nucleotide Analogues (NAs)*
 - 6.2.1. Introduction
 - 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.3. Interferons (IFNs)
- 6.4. Direct-Acting Antivirals (DAAs)
- 6.5. Others

7. GLOBAL HEPATITIS B AND C THERAPEUTICS MARKET, BY INDICATION

- 7.1. Introduction
 - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
 - 7.1.2. Market Attractiveness Index, By Indication
- 7.2. Hepatitis B (HBV)*
 - 7.2.1. Introduction
 - 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Hepatitis C (HCV)

8. GLOBAL HEPATITIS B AND C THERAPEUTICS MARKET, BY ROUTE OF

ADMINISTRATION

8.1. Introduction

8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

8.1.2. Market Attractiveness Index, By Route of Administration

8.2. Oral*

8.2.1. Introduction

8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

8.3. Injectable

9. GLOBAL HEPATITIS B AND C THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

9.1. Introduction

9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

9.1.2. Market Attractiveness Index, By Distribution Channel

9.2. Hospital Pharmacies*

9.2.1. Introduction

9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

9.3. Retail Pharmacies

10. GLOBAL HEPATITIS B AND C THERAPEUTICS MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES

10.1. Introduction

10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

10.1.2. Market Attractiveness Index, By Region

10.2. North America

10.2.1. Introduction

10.2.2. Key Region-Specific Dynamics

10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Class

10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication

10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10.2.7.1. U.S.

10.2.7.2. Canada

10.2.7.3. Mexico

10.3. Europe

10.3.1. Introduction

10.3.2. Key Region-Specific Dynamics

10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Class

10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication

10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10.3.7.1. Germany

10.3.7.2. UK

10.3.7.3. France

10.3.7.4. Spain

10.3.7.5. Italy

10.3.7.6. Rest of Europe

10.4. Asia-Pacific

10.4.1. Introduction

10.4.2. Key Region-Specific Dynamics

10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Class

10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication

10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10.4.7.1. China

10.4.7.2. India

10.4.7.3. Japan

10.4.7.4. South Korea

10.4.7.5. Rest of Asia-Pacific

10.4.8. South America

10.4.8.1. Introduction

10.4.8.2. Key Region-Specific Dynamics

10.4.8.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Class

10.4.8.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication

10.4.8.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

10.4.8.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10.4.8.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10.4.8.7.1. Brazil

10.4.8.7.2. Argentina

10.4.8.7.3. Rest of South America

10.5. Middle East and Africa

10.5.1. Introduction

10.5.2. Key Region-Specific Dynamics

10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Class

10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication

10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. COMPETITIVE LANDSCAPE AND MARKET POSITIONING

11.1. Competitive Overview and Key Market Players

11.2. Market Share Analysis and Positioning Matrix

11.3. Strategic Partnerships, Mergers & Acquisitions

11.4. Key Developments in Product Portfolios and Innovations

11.5. Company Benchmarking

12. COMPANY PROFILES

12.1. Gilead Sciences, Inc*

12.1.1. Company Overview

12.1.2. Product Portfolio

12.1.2.1. Product Description

12.1.2.2. Product Key Performance Indicators (KPIs)

12.1.3. Financial Overview

12.1.3.1. Company Revenue

12.1.3.2. Geographical Revenue Shares

12.1.3.3. Revenue Forecasts

12.1.4. Key Developments

12.1.4.1. Mergers & Acquisitions

12.1.4.2. Key Product Development Activities

12.1.4.3. Regulatory Approvals, etc.

12.1.4.4. SWOT Analysis

12.2. AbbVie Inc.

12.3. Bristol-Myers Squibb Company

- 12.4. Merck & Co., Inc.
- 12.5. Johnson & Johnson
- 12.6. Roche Holding AG
- 12.7. Dynavax Technologies Corporation
- 12.8. VBI Vaccines (LIST NOT EXHAUSTIVE)

13. ASSUMPTIONS AND RESEARCH METHODOLOGY

- 13.1. Data Collection Methods
- 13.2. Data Triangulation
- 13.3. Forecasting Techniques
- 13.4. Data Verification and Validation

14. APPENDIX

- 14.1. About Us and Services
- 14.2. Contact Us

I would like to order

Product name: Hepatitis B & C Therapeutics Market - 2024-2033

Product link: <https://marketpublishers.com/r/H6012651D208EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H6012651D208EN.html>